News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Celebrations may be in order for Innate Pharma S.A. (EPA:IPH) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The revenue forecast for this year has experienced a facelift, with analysts now much more optimistic on its sales pipeline.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Following the upgrade, the latest consensus from Innate Pharma's four analysts is for revenues of €98m in 2025, which would reflect a substantial 389% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of €85m in 2025. The consensus has definitely become more optimistic, showing a substantial gain in revenue forecasts.

See our latest analysis for Innate Pharma

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Innate Pharma's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 4x growth to the end of 2025 on an annualised basis. That is well above its historical decline of 14% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 24% per year. So it looks like Innate Pharma is expected to grow faster than its competitors, at least for a while.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They're also forecasting more rapid revenue growth than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Innate Pharma.

Better yet, Innate Pharma is expected to break-even soon - within the next few years - according to analyst forecasts, which would be a momentous event for shareholders. You can learn more about these forecasts, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.